Amplia reports a new confirmed partial response in Phase 2a pancreatic cancer trial. Picture Getty
Health & Biotech
Amplia Therapeutics (ASX: ATX) has announced that another patient in its Phase 2a ACCENT trial for advanced pancreatic cancer has shown a confirmed partial response.
This brings the total number of responders in the first patient group to four.
The ACCENT trial is investigating the effectiveness of narmafotinib, used in combination with standard chemotherapy, for treating advanced pancreatic cancer.
For the trial to move forward with the second cohort, at least six out of the 26 patients in the first cohort must show either a partial or complete response.
So far, three patients have met this criterion, and the latest confirmed response means only two more are required.
A “confirmed partial response” is defined as at least a 30% reduction in the size of tumour lesions, with no new lesions appearing, maintained over two months.
A “confirmed complete response”, meanwhile, means the total disappearance of tumour lesions for the same period.
Dr Chris Burns, CEO and Managing Director of Amplia, said that the positive results with narmafotinib align with previous clinical and preclinical findings.
“The activity of narmafotinib in the ACCENT trial continues to be very positive, consistent with our previous clinical and preclinical data.
“We remain on track to complete the interim analysis by the end of this quarter,” Dr Burns said,
The company will provide further updates on the trial as recruitment proceeds.
Compumedics (ASX: CMP), a medical device company, says it has secured a $1 million (EUR 0.6 million) order for its advanced Okti neurological wireless amplifier, which will be used by two prominent epilepsy hospitals in Berlin.
This latest order highlights the strong performance of Compumedics’ European business in FY24, where sales have surged by 63% compared to the previous year, reaching $7.6 million.
Much of this growth has been driven by the new Okti amplifier.
In addition to this recent success, sales in France, including key orders from CHU Angers and CHU Amiens Picardie, have established Compumedics as a major player in the field of pediatric neurology in the country.
The European market for Compumedics’ products is strong, estimated to be worth up to EUR 300 million annually, with a projected growth rate of 10%.
In Germany, the Okti amplifier has been selected by the Department of Neurology and the Berlin Institute of Health, Charité – Universitätsmedizin Berlin.
This contract comes after a rigorous two-year selection process involving several major epilepsy centres and health insurance companies.
The Okti amplifier stands out as the first high-definition portable EEG (electroencephalogram) device capable of recording both standard and high-density EEG with up to 128 channels.
The device is integrated with Compumedics’ Nexus 360 cloud-based solution, which has been recognised for its comprehensive and innovative approach to ambulatory long-term video EEG monitoring.
Meanwhile, EZZ Life Science (ASX:EZZ), a company focused on improving human health through genomic science, has unveiled four new ‘functional food’ products.
This marks EZZ’s entry into the functional foods sector, expanding its offerings designed to meet the nutritional needs of both children and adults.
The new products include EZZ Multi Vitamins Milk Powder and EZZ KidzSure Formulated Nutrition Powder, both for children aged 3 and up, as well as EZZ Lactoferrin Complex Powder for the same age group.
For adults, EZZ is introducing the EZZ VitalSure Formulated Nutrition Powder.
These products are manufactured in New Zealand and are formulated to provide essential vitamins, minerals, and nutrients.
EZZ aims to enhance its portfolio, particularly in the children’s category, which already includes popular items such as EZZ Bone Growth Chews and EZZ L-Lysine Growth Capsules.
To launch these new products, EZZ will utilise its well-established omnichannel distribution network, focusing on mainland China.
This strategy involves leveraging online platforms and retail stores to maximise reach and impact.
The functional foods market, especially in China, has been growing rapidly due to increased awareness of the importance of nutrition.
Market research indicates that the Asia-Pacific functional food and beverage market was valued at US$ 130.85 billion and is expected to grow at a rate of 10.46% annually from 2024 to 2032.
“We are thrilled to introduce our new adult and children’s nutrition range to the market,” said Glenn Cross, Chair of EZZ.
“With the increasing demand for high-quality nutrition products, we believe our new offerings will be well-received in the market, particularly in China.
“This launch reinforces our position as a provider of children’s nutrition products and sets the stage for growth in the functional foods category,” Cross added.
At Stockhead we tell it like it is. While EZZ Life Science is a Stockhead advertiser, it did not sponsor this article.
Health & Biotech
Health & Biotech
Health & Biotech
